BioNTech SE (22UA.F)

EUR 107.0

(-2.28%)

Operating Income Summary of BioNTech SE

BioNTech SE's latest annual operating income in 2023 was 690.4 Million EUR , down -94.54% from previous year.
BioNTech SE's latest quarterly operating income in 2024 Q2 was -703.03 Million EUR , down -36.62% from previous quarter.
BioNTech SE reported an annual operating income of 12.64 Billion EUR in 2022, down -17.28% from previous year.
BioNTech SE reported an annual operating income of 15.28 Billion EUR in 2021, up 18644.48% from previous year.
BioNTech SE reported a quarterly operating income of -514.61 Million EUR for 2024 Q1, down -197.8% from previous quarter.
BioNTech SE reported a quarterly operating income of -563.3 Million EUR for 2023 Q2, down -186.08% from previous quarter.

Annual Operating Income Chart of BioNTech SE (2023 - 2017)

Historical Annual Operating Income of BioNTech SE (2023 - 2017)

Year	Operating Income	Operating Income Growth
2023	690.4 Million EUR	-94.54%
2022	12.64 Billion EUR	-17.28%
2021	15.28 Billion EUR	18644.48%
2020	-82.41 Million EUR	54.6%
2019	-181.51 Million EUR	-237.06%
2018	-53.85 Million EUR	12.11%
2017	-61.27 Million EUR	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	-703.03 Million EUR	-36.62%
2024 Q1	-514.61 Million EUR	-197.8%
2023 Q2	-563.3 Million EUR	-186.08%
2023 Q4	526.2 Million EUR	619.84%
2023 FY	690.4 Million EUR	-94.54%
2023 Q3	73.1 Million EUR	112.98%
2023 Q1	654.4 Million EUR	-80.13%
2022 Q4	3.29 Billion EUR	37.92%
2022 Q2	2.2 Billion EUR	-53.51%
2022 Q1	4.75 Billion EUR	1.13%
2022 FY	12.64 Billion EUR	-17.28%
2022 Q3	2.38 Billion EUR	8.05%
2021 Q3	4.72 Billion EUR	12.51%
2021 Q1	1.66 Billion EUR	580.72%
2021 Q2	4.19 Billion EUR	152.58%
2021 FY	15.28 Billion EUR	18644.48%
2021 Q4	4.69 Billion EUR	-0.5%
2020 FY	-82.41 Million EUR	54.6%
2020 Q4	244.18 Million EUR	231.01%
2020 Q3	-186.38 Million EUR	-130.27%
2020 Q2	-80.94 Million EUR	-36.55%
2020 Q1	-59.27 Million EUR	-11.96%
2019 Q1	-43.83 Million EUR	-1728.74%
2019 Q3	-36.87 Million EUR	22.97%
2019 Q4	-52.94 Million EUR	-43.58%
2019 FY	-181.51 Million EUR	-237.06%
2019 Q2	-47.86 Million EUR	-9.2%
2018 Q2	-14.91 Million EUR	0.0%
2018 Q1	-14.91 Million EUR	0.0%
2018 Q3	-21.62 Million EUR	-45.01%
2018 Q4	-2.39 Million EUR	88.92%
2018 FY	-53.85 Million EUR	12.11%
2017 FY	-61.27 Million EUR	0.0%

Peer Operating Income Comparison of BioNTech SE

Name	Operating Income	Operating Income Difference
CureVac N.V.	-274.2 Million EUR	351.781%
Biotest Aktiengesellschaft	143.5 Million EUR	-381.115%
Biotest Aktiengesellschaft	143.5 Million EUR	-381.115%
BRAIN Biotech AG	-6.71 Million EUR	10381.459%
Formycon AG	-369 Thousand EUR	187200.271%
Heidelberg Pharma AG	-21.2 Million EUR	3355.099%
Medigene AG	-16.14 Million EUR	4375.187%